Allysta Pharmaceuticals, Inc

Allysta Pharmaceuticals is a US-based private clinical stage biopharmaceutical with a platform technology targeting treatment of fibrotic diseases offering broad applicability across a range of diseases. We are particularly focused on rare fibrotic diseases that qualify for the advantages associated with Orphan Drug Designation, including rare conditions involving the muscle, lung, liver, and eye. Our lead drug candidate, ALY688, is a first-in-class multi-functional anti-fibrotic peptide with additional anti-inflammatory and cell regenerative actions targeting Duchenne muscular dystrophy, a devastating genetic disease of young boys and is ready to enter human clinical trials.